Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor

Clinical Pharmacology: Advances and Applications

Volumn 5, Issue , 2013, Pages 59-66

  Upreti, Vijay V ^a   Song, Yan ^a   Wang, Jessie ^b   Byon, Wonkyung ^c   Boyd, Rebecca A ^c   Pursley, Janice M ^b   Lacreta, Frank ^a   Frost, Charles E ^a  

^a Discovery Medicine and Clinical Pharmacology   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c PFIZER INC   (United States)

Author keywords

Apixaban; Drug drug interaction; Factor Xa inhibitor; Famotidine; H2 receptor antagonists; hOCT inhibitor

Indexed keywords

APIXABAN; FAMOTIDINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEMATOMA; HUMAN; HUMAN EXPERIMENT; INTERNATIONAL NORMALIZED RATIO; LIMIT OF QUANTITATION; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; OPEN STUDY; PLASMA CONCENTRATION-TIME CURVE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; STOMACH PH; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 84876996914     PISSN: None     EISSN: 11791438     Source Type: Journal    
DOI: 10.2147/CPAA.S41999     Document Type: Article

References (27)

1. Pinto DJ, Orwat MJ, Koch S, et al. Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, effcacious, and orally bioavailable inhibitor of blood coagulation factor Xa. J Med Chem. 2007;50(22):5339-5356.
2. Wong PC, Crain EJ, Xin B, et al. Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies. J Thromb Haemost. 2008;6(5):820-829.
3. Kaiser B. Factor Xa - a promising target for drug development. Cell Mol Life Sci. 2002;59(2):189-192.
4. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med. 2009;361(6):594-604.
5. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet. 2010;375(9717):807-815.
6. Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med. 2010;363(26):2487-2498.
7. Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fbrillation. N Engl J Med. 2011;364(9):806-817.
8. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fbrillation. N Engl J Med. 2011;365(11): 981-992.
9. Buller H, Deitchman D, Prins M, Segers A. Effcacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. J Thromb Haemost. 2008;6(8):1313-1318.
10. Agnelli G, Buller HR, Cohen A, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013;368(8): 699-708.
11. Frost C, Yu Z, Moore K, et al. Apixaban, an oral direct factor Xa inhibitor: multiple-dose safety, pharmacokinetics, and pharmacodynam-ics in healthy subjects. J Thromb Haemost. 2007;5 Suppl 2:P-M-664.
12. Frost C, Wang J, Nepal S, et al. Apixaban, an oral, direct factor Xa inhibitor: single-dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Br J Clin Pharmacol. 2013;75(2): 476-487.
13. Wang L, Zhang D, Raghavan N, et al. In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies. Drug Metab Dispos. 2010;38(3):448-458.
14. Frost C, Yu Z, Nepal S, et al. Apixaban, a direct factor Xa inhibitor: single-dose pharmacokinetics and pharmacodynamics of an intravenous formulation. J Clin Pharmacol. 2008;48:1132.
15. Raghavan N, Frost CE, Yu Z, et al. Apixaban metabolism and phar-macokinetics after oral administration to humans. Drug Metab Dispos. 2009;37(1):74-81.
16. Vakkalagadda B, Frost C, Wang J, et al. Effect of rifampin on the phar-macokinetics of apixaban, an oral direct inhibitor of factor Xa. J Clin Pharmacol. 2009;49:1124.
17. Sonnenberg A. The US temporal and geographic variations of diseases related to Helicobacter pylori. Am J Public Health. 1993;83(7): 1006-1010.
18. Majumdar SR, Soumerai SB, Farraye FA, et al. Chronic acid-related disorders are common and underinvestigated. Am J Gastroenterol. 2003;98(11):2409-2414.
19. Echizen H, Ishizaki T. Clinical pharmacokinetics of famotidine. Clin Pharmacokinet. 1991;21(3):178-194.
20. Pepcid [package insert]. Whitehouse Station, NJ: Merck and Co, Inc; 2010.
21. Bologna M, Napolitano T, Biordi L, Carlucci G. HPLC reveals famo-tidine in the urine up to fve days after a single 20 mg oral dose. Drugs Exp Clin Res. 1988;14(6):419-421.
22. Humphries TJ. Famotidine: a notable lack of drug interactions. Scand J Gastroenterol Suppl. 1987;134:55-60.
23. Klotz U, Arvela P, Rosenkranz B. Famotidine, a new H2-receptor antagonist, does not affect hepatic elimination of diazepam or tubular secretion of procainamide. Eur J Clin Pharmacol. 1985;28(6):671-675.
24. Lin JH, Chremos AN, Chiou R, Ye h KC, Williams R. Comparative effect of famotidine and cimetidine on the pharmacokinetics of theophylline in normal volunteers. Br J Clin Pharmacol. 1987;24(5):669-672.
25. Bourdet DL, Pritchard JB, Thakker DR. Differential substrate and inhibitory activities of ranitidine and famotidine toward human organic cation transporter 1 (hOCT1; SLC22A1), hOCT2 (SLC22A2), and hOCT3 (SLC22A3). J Pharmacol Exp Ther. 2005;315(3):1288-1297.
26. Diletti E, Hauschke D, Steinijans V W. Sample size determination for bioequivalence assessment by means of confdence intervals. Int J Clin Pharmacol Ther Toxicol. 1991;29(1):1-8.
27. Barrett YC, Wang J, Song Y, et al. A randomised assessment of the pharmacokinetic, pharmacodynamic and safety interaction between apixaban and enoxaparin in healthy subjects. Thromb Haemost. 2012; 107(5):916-924.